The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making an
The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.
대표청구항▼
1. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs); andat least two porins; anda pharmaceutically acceptable carrier;wherein the gram negative microbes comprise
1. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs); andat least two porins; anda pharmaceutically acceptable carrier;wherein the gram negative microbes comprise members of the family Vibrionaceae. 2. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs); andat least two porins; anda pharmaceutically acceptable carrier:,wherein the gram negative microbes comprise Campylobacter spp. 3. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs); andat least two porins; anda pharmaceutically acceptable carrier;wherein the gram negative microbes comprise Actinobacillus spp., Haemophilus spp., Myxcobacteria spp., Sporocytophaga spp., Chondrococcus spp., Cytophaga spp., Flexibacter spp., Flavobacterium spp., Aeromonas spp., or any combination thereof. 4. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs) expressed by the gram negative microbe when the gram negative microbe is grown in the presence of 2,2-dipyridyl; andat least two porins; anda pharmaceutically acceptable carrier. 5. The composition of claim 4 wherein the SRPs comprise SRPs that are expressed by the gram negative microbe when the gram negative microbe is grown in the presence of 24 μg/mL 2,2-dipyridyl. 6. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs), wherein at least one SRP is not expressed by the gram negative microbe at a detectable level when the gram negative microbe is grown in the absence of 2,2-dipyridyl; andat least two porins; anda pharmaceutically acceptable carrier. 7. The composition of claim 6 wherein at least one SRP comprises an SRP that is not expressed by the gram negative microbe at a detectable level when the gram negative microbe is grown in the absence of 24 μg/mL 2,2-dipyridyl. 8. The composition of claim 1 further comprising an adjuvant. 9. The composition of claim 1 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 10. The composition of claim 1 wherein the pharmaceutically acceptable carrier comprises an implant. 11. A composition comprising: whole cells comprising: a plurality of siderophore receptor polypeptides (SRPs) expressed by a gram negative microbe; anda plurality of porins expressed by the gram negative microbe; anda pharmaceutically acceptable carrier;wherein the gram negative microbes comprise members of the family Vibrionaceae. 12. A composition comprising: whole cells comprising: a plurality of siderophore receptor polypeptides (SRPs) expressed by a gram negative microbe; anda plurality of porins expressed by the gram negative microbe; anda pharmaceutically acceptable carrier;wherein the gram negative microbes comprise Campylobacter spp. 13. A composition comprising: whole cells comprising: a plurality of siderophore receptor polypeptides (SRPs) expressed by a gram negative microbe; anda plurality of porins expressed by the gram negative microbe; anda pharmaceutically acceptable carrier;wherein the gram negative microbes comprise Actinobacillus spp., Haemophilus spp., Myxcobacteria spp., Sporocytophaga spp., Chondrococcus spp., Cytophaga spp., Flexibacter spp., Flavobacterium spp., Aeromonas spp., or any combination thereof. 14. A composition comprising: whole cells comprising: a plurality of siderophore receptor polypeptides (SRPs) expressed by a gram negative microbe when the gram negative microbe is grown in the presence of 2,2-dipyridyl; anda plurality of porins expressed by the gram negative microbe; anda pharmaceutically acceptable carrier. 15. The composition of claim 14 wherein the SRPs comprise SRPs that are expressed by the gram negative microbe when the gram negative microbe is grown in the presence of 24 μg/mL 2,2-dipyridyl. 16. A composition comprising: whole cells comprising: a plurality of siderophore receptor polypeptides (SRPs) expressed by a gram negative microbe, wherein at least one SRP is not expressed by the gram negative microbe at a detectable level when the gram negative microbe is grown in the absence of 2,2-dipyridyl; anda plurality of porins expressed by the gram negative microbe; anda pharmaceutically acceptable carrier. 17. The composition of claim 16 wherein at least one SRP comprises an SRP that is not expressed by the gram negative microbe at a detectable level when the gram negative microbe is grown in the absence of 24 μg/mL 2,2-dipyridyl. 18. The composition of claim 11 further comprising an adjuvant. 19. The composition of claim 11 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 20. The composition of claim 11 wherein the pharmaceutically acceptable carrier comprises an implant. 21. A composition comprising: an isolated whole cell preparation of gram negative microbes, wherein the gram negative microbes comprise: at least two siderophore receptor polypeptides (SRPs); andat least two porins; anda pharmaceutically acceptable carrier;wherein the gram negative microbe comprises an E. coli mutant lacking outer oligosaccharide side chains of LPS. 22. A composition comprising: whole cells comprising: a plurality of siderophore receptor polypeptides (SRPs) expressed by a gram negative microbe; anda plurality of porins expressed by the gram negative microbe; anda pharmaceutically acceptable carrier;wherein the gram negative microbe comprises an E. coli mutant lacking outer oligosaccharide side chains of LPS. 23. The composition of claim 2 further comprising an adjuvant. 24. The composition of claim 2 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 25. The composition of claim 2 wherein the pharmaceutically acceptable carrier comprises an implant. 26. The composition of claim 3 further comprising an adjuvant. 27. The composition of claim 3 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 28. The composition of claim 3 wherein the pharmaceutically acceptable carrier comprises an implant. 29. The composition of claim 4 further comprising an adjuvant. 30. The composition of claim 4 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 31. The composition of claim 4 wherein the pharmaceutically acceptable carrier comprises an implant. 32. The composition of claim 6 further comprising an adjuvant. 33. The composition of claim 6 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 34. The composition of claim 6 wherein the pharmaceutically acceptable carrier comprises an implant. 35. The composition of claim 12 further comprising an adjuvant. 36. The composition of claim 12 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 37. The composition of claim 12 wherein the pharmaceutically acceptable carrier comprises an implant. 38. The composition of claim 13 further comprising an adjuvant. 39. The composition of claim 13 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 40. The composition of claim 13 wherein the pharmaceutically acceptable carrier comprises an implant. 41. The composition of claim 14 further comprising an adjuvant. 42. The composition of claim 14 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 43. The composition of claim 14 wherein the pharmaceutically acceptable carrier comprises an implant. 44. The composition of claim 16 further comprising an adjuvant. 45. The composition of claim 16 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 46. The composition of claim 16 wherein the pharmaceutically acceptable carrier comprises an implant. 47. The composition of claim 21 further comprising an adjuvant. 48. The composition of claim 21 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 49. The composition of claim 21 wherein the pharmaceutically acceptable carrier comprises an implant. 50. The composition of claim 22 further comprising an adjuvant. 51. The composition of claim 22 wherein the pharmaceutically acceptable carrier comprises a biocompatible matrix. 52. The composition of claim 22 wherein the pharmaceutically acceptable carrier comprises an implant.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (45)
Daryll A. Emery ; Darren E. Straub ; Richard Huisinga ; Beth A. Carlson, Active immunization using a siderophore receptor protein.
Potter Andrew A. (Saskatoon CAX) Harland Richard J. (Saskatoon CAX), Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins.
Schryvers Anthony B. (Calgary CAX), Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of va.
Blake Milan S. (New York NY) Tai Joseph Y. (Fort Washington PA) Qi Huilin L. (New York NY) Liang Shu-Mei (Bethesda MD) Hronowski Lucjan J. J. (Laurel MD) Pullen Jeffrey K. (Columbia MD), Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Ne.
Emery Daryll A. (Willmar MN) Straub Darren E. (Willmar MN) Huisinga Richard (Willmar MN), Method of priming an immune response in a one-day old animal.
Emery,Daryll A.; Straub,Darren E.; Zammert,Donavan E.; Kallevig,Gayla K., Methods for making compositions including gram negative microbial polypeptides.
Emery, Daryll A.; Straub, Darren E.; Wonderling, Laura; Herron Olson, Lisa L., Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
Emery, Daryll A.; Straub, Darren E.; Wonderling, Laura; Herron Olson, Lisa L., Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
Emery, Daryll A.; Straub, Darren E.; Wonderling, Laura; Herron Olson, Lisa L., Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
Tam, Patricia E.; Harris, Michael Nathan; Tripp, Timothy James; Lobo, Sandra, Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use.
Emery, Daryll A.; Straub, Darren E.; Herron-Olson, Lisa L.; Wonderling, Laura, Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
Emery, Daryll A.; Straub, Darren E.; Herron-Olson, Lisa L.; Wonderling, Laura, Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
Emery, Daryll A.; Straub, Darren E.; Herron-Olson, Lisa L.; Wonderling, Laura, Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
Emery, Daryll A.; Straub, Darren E.; Wonderling, Laura; Herron Olson, Lisa L., Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.